Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)

by NASDAQ Market News September 17, 2021

NASDAQ Market News
Click here to email author

Elicio Therapeutics Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant at the Vaccines Summit 2021

Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares

Ads